Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0284267 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Hadi Darvishi-Khezri und 7 weiteren Autor:innen. Beteiligte Einrichtung: Thalassemia Research Center (TRC), Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran. Hauptthemen laut MEDLINE: beta-Thalassemia, Iron Overload, Thalassemia, Hepatitis C. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aim Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and β-Thalassemia patients. We aimed to evaluate the level of serum zinc in β-thalassemia patients with DM and a risk assessment for hypozincemia.
Methods
The study population included transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) with overt DM (fasting plasma glucose (FPG) ≥126 mg/dL, and/or 2-h plasma glucose≥200 mg/dL). Serum zinc concentration was measured by the colorimetric method, and the values below 70 μg/dL were defined as hypozincemia. Myocardial and liver T2*-weighted magnetic resonance imaging (MRI T2*, millisecond [ms]) were valued by a free contrast MRI. The demographic, clinical, paraclinical, and laboratory data were also recorded. The data belonged to the period from December 2018 until December 2020.
Results
Of 64 diabetic β-thalassemia patients, 41 cases had zinc data in their medical files (aged 38 ± 9 years, 48.8% female). 78.05% of patients (n = 32) were TDT, and 21.95% were NTDT (n = 9). The mean ± standard deviation of zinc level was 110.2 ± 127.6 μg/dL. The prevalence of hypozincemia was 9.76%, 95% confidence interval [CI] 0.27 to 19.24 (four cases). After controlling age, the odds of hypozincemia for using deferasirox (DFX) was 8.77, 95% CI 0.60 to 127.1. In β-thalassemia patients, the age-adjusted risk of hypozincemia was calculated at 15.85, 95% CI 0.47 to 529.3 for hepatitis C. The adjusted risk of hypozincemia based on age for antacid use was 6.34, 95% CI 0.39 to 102.7.
Conclusion
In light of this study, as well as hepatitis C, using DFX and antacids is associated with a high risk of hypozincemia amid diabetic β-thalassemia cases. However, upward bias should be taken into consideration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Thalassemia Research Center (TRC), Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
- Gut and Liver Research Center, Non-communicable Disease Institute, Mazandaran University of Medical Sciences, Sari, Iran.
- MD. Islamic Azad University, Sari Branch, Mazandaran, Iran.
- Department of Pediatrics, Mazandaran University of Medical Sciences, Sari, Iran.
ORCID-Profile: Hossein Karami, Mobin Ghazaiean
Zitieren
APA
Darvishi-Khezri, H., Karami, H., Naderisorki, M., Ghazaiean, M., Kosaryan, M., Mosanejad-Galchali, A., Aliasgharian, A., & Karami, H. (2024). Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. PLOS ONE. https://doi.org/10.1371/journal.pone.0284267
Vancouver
Darvishi-Khezri H, Karami H, Naderisorki M, Ghazaiean M, Kosaryan M, Mosanejad-Galchali A, et al. Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox. PLOS ONE. 2024. doi:10.1371/journal.pone.0284267
BibTeX
@article{DarvishiKhezri2024,
author = {Darvishi-Khezri, Hadi and Karami, Hossein and Naderisorki, Mohammad and Ghazaiean, Mobin and Kosaryan, Mehrnoush and Mosanejad-Galchali, Amir and Aliasgharian, Aily and Karami, Hasan},
title = {Two risk factors for hypozincemia in diabetic β-thalassemia patients: Hepatitis C and deferasirox},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0284267}
}
EUVIMED